KR20210091992A - Composition for preventing or treating hair loss comprising tiplaxtinin - Google Patents
Composition for preventing or treating hair loss comprising tiplaxtinin Download PDFInfo
- Publication number
- KR20210091992A KR20210091992A KR1020200005397A KR20200005397A KR20210091992A KR 20210091992 A KR20210091992 A KR 20210091992A KR 1020200005397 A KR1020200005397 A KR 1020200005397A KR 20200005397 A KR20200005397 A KR 20200005397A KR 20210091992 A KR20210091992 A KR 20210091992A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- composition
- tiplaxtinin
- preventing
- hair loss
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- ODXQFEWQSHNQNI-UHFFFAOYSA-N Tiplasinin Chemical compound C12=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 ODXQFEWQSHNQNI-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 39
- 208000024963 hair loss Diseases 0.000 title claims abstract description 35
- 230000003676 hair loss Effects 0.000 title claims abstract description 27
- 230000003779 hair growth Effects 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 13
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 12
- 230000001737 promoting effect Effects 0.000 claims abstract description 9
- 210000004918 root sheath Anatomy 0.000 claims abstract description 6
- 210000004209 hair Anatomy 0.000 claims description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008159 sesame oil Substances 0.000 claims description 14
- 235000011803 sesame oil Nutrition 0.000 claims description 14
- 230000003752 improving hair Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 239000008266 hair spray Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000003658 preventing hair loss Effects 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 12
- 210000004761 scalp Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- -1 Tiflaxtinin Substances 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 210000002488 outer root sheath cell Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 티플락스티닌을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating hair loss containing tiplaxtinin as an active ingredient.
탈모(alopecia)는 정상적으로 모발이 자라지 못하여 쉽게 빠지고 가늘어지며 성장기가 짧아짐과 동시에 휴지기가 길어지는 현상이다. 머리카락은 정상적으로 하루에 50-100개 정도 피부로부터 빠져나가지만, 매일 100개 이상 지속적으로 빠지게 되면 탈모증 환자로 생각할 수 있다. Alopecia is a phenomenon in which the hair does not grow normally, so it falls out easily and becomes thin, and the growth period is shortened and the resting period is prolonged at the same time. Normally, about 50-100 hairs fall out of the skin per day, but if more than 100 hairs fall out continuously every day, you can be considered alopecia patients.
최근 급속한 경제 성장과 생활수준의 향상으로 사람들의 삶의 질은 향상되었으나, 이에 따른 공해와 환경오염의 발생으로 인해 현대인들은 외부의 자극과 각종 질병에 노출되어 있다. 특히 모발과 관련하여 국소감염, 유전적 소인, 내분비 장애 등에 의해 탈모증이 발병된다고 밝혀졌으나, 최근의 연구에서는 스트레스, 환경오염에 의한 부작용 등 탈모에 관련한 다양한 요인들이 작용하는 것으로 나타났다.Recently, people's quality of life has improved due to rapid economic growth and improvement of living standards, but modern people are exposed to external stimuli and various diseases due to the occurrence of pollution and environmental pollution. In particular, it has been found that alopecia is caused by local infection, genetic predisposition, endocrine disorders, etc. in relation to hair, but in recent studies, various factors related to hair loss such as stress and side effects due to environmental pollution have been shown to act.
탈모의 유발 기전 중에서도 특히 스트레스 등의 환경 요인에 의해 면역 세포와 호중구가 활성화되어 염증 반응을 일으키게 되고 모낭 조직을 파괴하여 모발 세포의 세포사를 유발하여 탈모가 진행되게 된다. 이에, 남성의 고민이라고 알려져 왔던 탈모가 최근에는 여성 탈모, 젊은 층의 탈모로 이어져 이에 대한 예방 및 치료에 대한 요구가 커지고 있다. Among the mechanisms of hair loss, in particular, immune cells and neutrophils are activated by environmental factors such as stress, causing an inflammatory reaction, and destroying the hair follicle tissue to induce cell death of hair cells, leading to hair loss. Accordingly, hair loss, which has been known to be a problem for men, has recently led to female hair loss and hair loss among young people, increasing the demand for prevention and treatment.
현재까지 상업화되어 시장에 나와 있는 각종 제품들의 탈모증의 치료와 예방에 관한 효과는 의약품의 경우 제품을 꾸준히 사용하는 동안 약간의 유효율을 나타내지만 사용을 중단하면 다시 탈모가 원래대로 진행되고, 두피에 도포하는 의약외품의 경우 미약한 효과가 있는 정도이지만 이 제품들 역시 사용을 중단하면 다시 탈모가 급격히 진행되는 경우가 많고 사용이 불편한 단점이 있다.The effects on the treatment and prevention of alopecia of various products that have been commercialized and are on the market to date show a slight effectiveness rate while the product is used continuously, but when the use is stopped, the hair loss proceeds again and is applied to the scalp. In the case of quasi-drugs, which have a weak effect, these products also have the disadvantage of being inconvenient to use and in many cases hair loss occurs rapidly again when the use of these products is stopped.
또한, 국소용 또는 경구용으로 투여되는 미녹시딜의 경우는 두피의 홍반, 염증, 감염, 자극 또는 동통 등 피부에 자극이 있으며, 혈압강하 효과가 있으므로 혈압강하제를 투여 중인 환자를 포함한 고혈압 환자에게는 신중한 투여를 요하는 등의 문제점이 있다. In addition, in the case of minoxidil administered for topical or oral use, there is irritation to the skin such as erythema, inflammation, infection, irritation or pain of the scalp, and since it has a blood pressure lowering effect, careful administration to hypertensive patients including patients taking antihypertensive drugs There are problems such as requiring
이에, 보다 효과적이고 안전한 새로운 탈모 치료제에 대한 지속적인 연구 개발이 요구되고 있는 실정이다.Accordingly, there is a demand for continuous research and development for a new, more effective and safe treatment for hair loss.
상기와 같은 문제점을 해결하기 위해, 본 발명은 보다 우수한 효과를 가진 탈모 예방 또는 치료용 조성물을 제공한다.In order to solve the above problems, the present invention provides a composition for preventing or treating hair loss having a more excellent effect.
본 발명에 따른 탈모 예방 또는 치료용 약학 조성물은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유할 수 있다.The pharmaceutical composition for preventing or treating hair loss according to the present invention may contain Tiplaxtinin as an active ingredient.
본 발명에 따른 탈모 예방 또는 개선용 화장료 조성물은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유할 수 있다.The cosmetic composition for preventing or improving hair loss according to the present invention may contain Tiplaxtinin as an active ingredient.
본 발명에 따른 탈모 예방 또는 개선용 건강식품 조성물은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유할 수 있다.The health food composition for preventing or improving hair loss according to the present invention may contain Tiplaxtinin as an active ingredient.
본 발명에 따른 발모 촉진용 조성물은 티플락스티닌(Tiplaxtinin)이 함유된 전달체를 유효성분으로 함유할 수 있다.The composition for promoting hair growth according to the present invention may contain a carrier containing Tiplaxtinin as an active ingredient.
본 발명에 따른 탈모 예방 또는 치료용 조성물은 모낭 외모근초(ORS) 세포를 증식시키고, 모발 성장을 촉진시키는 티플락스티닌을 유효성분으로 함유함으로써, 보다 효과적이고 안전하게 탈모를 예방, 개선 또는 치료할 수 있다.The composition for preventing or treating hair loss according to the present invention can prevent, improve or treat hair loss more effectively and safely by proliferating hair follicle outer root sheath (ORS) cells and containing tiplaxtinin, which promotes hair growth, as an active ingredient. .
또한, 본 발명에 따른 발모 촉진용 조성물은 티플락스티닌을 함유한 전달체를 이용함으로써, 발모 효과를 증진시켜 보다 효과적으로 탈모를 예방, 개선 또는 치료할 수 있다.In addition, the composition for promoting hair growth according to the present invention can prevent, improve or treat hair loss more effectively by enhancing the hair growth effect by using a carrier containing tiplaxtinin.
도 1은 본 발명의 일 실시예에 따라 티플락스티닌 용액 처리에 따른 모낭 외모근초세포 수를 나타낸 그래프이다.
도 2는 본 발명의 일 실시예에 따른 티플락스티닌 용액 처리 농도별 상대적 모발 길이 변화를 측정한 결과이다.
도 3은 본 발명의 일 실시예에 따른 티플락스티닌을 함유한 운반체의 효능을 확인한 동물 실험의 결과를 나타낸 이미지이다.1 is a graph showing the number of hair follicle superficial myoblast cells according to the treatment with a tiplaxtinin solution according to an embodiment of the present invention.
2 is a result of measuring the relative hair length change according to the treatment concentration of the tiplaxtinin solution according to an embodiment of the present invention.
3 is an image showing the results of an animal experiment confirming the efficacy of a carrier containing tiplaxtinin according to an embodiment of the present invention.
이하, 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명자는 티플락스티닌(Tiplaxtinin)을 탈모 환자의 후두부 외모근초세포(outer root sheath cell) 및 배양된 모낭조직에 다양한 농도로 처리한 결과, 대조군 대비 외모근초세포의 증식과 모발 길이 증가 등 유의한 효과를 확인하였고, 생쥐 in vivo 실험에서 대조군보다 티플락스티닌 처리 군에서 모낭 생장기 유도가 월등히 높음을 확인함으로써, 본 발명을 완성하였다.The present inventors treated the occipital outer root sheath cells and the cultured hair follicle tissue with Tiplaxtinin at various concentrations, compared to the control group, as a result of which the proliferation of the outer root sheath cells and the increase in hair length were significant. The effect was confirmed, and the present invention was completed by confirming that the induction of hair follicle growth phase was significantly higher in the tiplaxtinin-treated group than in the control group in the mouse in vivo experiment.
본 발명은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유하는 탈모 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating hair loss containing Tiplaxtinin as an active ingredient.
상기 티플락스티닌은 모낭 외모근초(ORS) 세포를 증식시키고, 모발 성장을 촉진시킬 수 있어, 탈모 예방 또는 치료용 약학 조성물로 사용될 수 있다.The tiplaxtinin can proliferate hair follicle outer root sheath (ORS) cells and promote hair growth, and thus can be used as a pharmaceutical composition for preventing or treating hair loss.
본 발명에 따른 약학 조성물은 유효성분인 상기 티플락스티닌 외에 약학적으로 허용되는 담체, 부형제 등을 더 포함할 수 있고, 국소형 제형, 예를 들어, 크림, 로션, 연고(반고형의 외용약), 마이크로에멀젼, 젤, 페이스트, 경피제제(TTS)(패치제, 붕대 등) 등으로 제조될 수 있다. 상기에서 "약학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응 가능한 이상의 독성을 지니지 않는다는 의미이다.The pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, etc., in addition to the active ingredient, Tiflaxtinin, and topical formulations, for example, creams, lotions, ointments (semi-solid external drugs) , microemulsions, gels, pastes, transdermal preparations (TTS) (patches, bandages, etc.), and the like. In the above, "pharmaceutically acceptable" means that it does not inhibit the activity of the active ingredient and does not have toxicity beyond what the application (prescription) target can adapt.
상기 약학적으로 허용되는 담체는 락토스, 글루코스, 슈크로스, 전분(옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스, 등), 맥아, 젤라틴, 탈크, 고체 윤활제(스테아르산, 스테아르산 마그네슘 등), 황산칼슘, 식물성 기름(땅콩기름, 면실유, 참기름, 올리브유 등), 폴리올(프로필렌글리콜, 글리세린 등), 알긴산, 유화제(TWEENS), 습윤제(라우릴 황산나트륨), 착색제, 풍미제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 포함할 수 있다. 이러한 담체는 본 발명의 약학 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.The pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (corn starch, potato starch, etc.), cellulose, derivatives thereof (sodium carboxymethyl cellulose, ethyl cellulose, etc.), malt, gelatin, talc, solid lubricants. (stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oil (peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyol (propylene glycol, glycerin, etc.), alginic acid, emulsifier (TWEENS), wetting agent (sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffered solutions, and the like. One or more suitable carriers may be selected and used according to the formulation of the pharmaceutical composition of the present invention.
부형제도 본 발명의 약학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예를 들어, 나트륨 카르복시메틸 셀룰로오스, 메틸셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 포함할 수 있다.Excipients may also be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, sodium carboxymethyl cellulose, methyl cellulose, hydropropyl methyl cellulose, sodium alginate, polyvinyl pyrrolidone suspending or dispersing agents such as and the like.
본 발명에 따른 약학 조성물은 다른 탈모 예방 또는 치료용 약물이나 보조제를 더 포함하여 복합제제로도 사용될 수 있다. 예를 들어, 미녹시딜(minoxidil), 피나스테라이드 등의 탈모 치료제를 더 포함할 수 있고, 병풍 추출물, 로즈마리 추출물, 해초 추출물 등의 천연 추출물을 더 포함할 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition according to the present invention may also be used as a combination preparation by further including other drugs or adjuvants for preventing or treating hair loss. For example, it may further include a hair loss treatment agent such as minoxidil and finasteride, and may further include a natural extract such as a folding screen extract, a rosemary extract, and a seaweed extract, but is not limited thereto.
본 발명에 따른 약학 조성물은 경구 또는 비경구로 투여될 수 있고, 바람직하게는 두피, 특히 두피의 탈모 부위나 모발에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 투여될 수 있다. 상기 약학 조성물의 1일 투여량은 통상 0.001~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 이는 투여자의 필요에 따라 증감할 수 있으며, 두피의 상태, 탈모의 진행 정도 등 상황에 따라 적절히 증감할 수 있다.The pharmaceutical composition according to the present invention may be administered orally or parenterally, preferably by a transdermal administration method such as direct application or spraying to the scalp, particularly the hair loss area or hair of the scalp. The daily dose of the pharmaceutical composition is usually in the range of 0.001 to 150 mg/kg body weight, and may be administered once or divided into several doses. This may be increased or decreased according to the needs of the administering agent, and may be appropriately increased or decreased depending on the situation, such as the condition of the scalp and the degree of hair loss.
본 발명은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유하는 탈모 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving hair loss containing Tiplaxtinin as an active ingredient.
상기 티플락스티닌은 모낭 외모근초(ORS) 세포를 증식시키고, 모발 성장을 촉진시킬 수 있어, 탈모 예방 또는 개선용 화장료 조성물로 사용될 수 있다.The tiplaxtinin can proliferate hair follicle outer root sheath (ORS) cells and promote hair growth, and thus can be used as a cosmetic composition for preventing or improving hair loss.
본 발명에 따른 화장료 조성물은 당업계의 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있고, 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말, 샴푸 및 스프레이 등으로 제형화될 수 있으나, 이에 제한되는 것은 아니다. The cosmetic composition according to the present invention may be prepared in any formulation conventionally prepared in the art, and may include solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents, oils, It may be formulated as a powder, shampoo and spray, but is not limited thereto.
바람직하게는 상기 화장료 조성물은 모발, 두피에 사용하는 모든 형태의 화장료로 제조될 수 있고, 예를 들어, 상기 화장료 조성물은 티플락스티닌을 유효성분으로 함유하는 헤어토닉, 헤어크림, 헤어에센스, 헤어로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어스프레이, 헤어에어졸, 헤어팩, 헤어왁스, 헤어염색제 또는 헤어젤의 제형으로 제조될 수 있다. Preferably, the cosmetic composition may be prepared from any type of cosmetic used for hair and scalp. For example, the cosmetic composition may include a hair tonic, hair cream, hair essence, and hair containing tiplaxtinin as an active ingredient. It may be prepared in the form of lotion, hair shampoo, hair rinse, hair treatment, hair spray, hair aerosol, hair pack, hair wax, hair dye or hair gel.
상기 화장료 조성물은 상기 티플락스티닌 외에 모발 화장료 제제에 있어서 수용 가능한 담체를 포함할 수 있다. 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 방부제, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료, 희석제 등이 포함될 수 있다.The cosmetic composition may include an acceptable carrier in the hair cosmetic preparation in addition to the tiplaxtinin. The carrier may include alcohol, oil, surfactant, fatty acid, silicone oil, preservative, humectant, humectant, viscosity modifier, emulsion, stabilizer, sunscreen, color developer, fragrance, diluent, and the like.
상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 방부제, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료, 희석제 등으로 사용될 수 있는 구체적인 화합물 또는 조성물은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 화합물 또는 조성물을 선택하여 사용할 수 있다.Specific compounds or compositions that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, preservative, wetting agent, humectant, viscosity modifier, emulsifier, stabilizer, sunscreen, color developer, fragrance, diluent, etc. are already known in the art. Therefore, those skilled in the art can select and use an appropriate compound or composition.
또한, 상기 화장료 조성물은 그 효과를 증진시키고 부작용을 최소화하기 위해 피부 흡수 촉진제, 두피 보호제 또는 두피 활성제 등을 더 포함할 수 있다.In addition, the cosmetic composition may further include a skin absorption accelerator, a scalp protectant, or a scalp active agent to enhance the effect and minimize side effects.
본 발명은 티플락스티닌(Tiplaxtinin)을 유효성분으로 함유하는 탈모 예방 또는 개선용 건강식품 조성물을 제공한다.The present invention provides a health food composition for preventing or improving hair loss containing Tiplaxtinin as an active ingredient.
상기 티플락스티닌은 모낭 외모근초(ORS) 세포를 증식시키고, 모발 성장을 촉진시킬 수 있어, 탈모 예방 또는 개선용 건강식품 조성물로 사용될 수 있다. The tiplaxtinin can proliferate hair follicle outer root sheath (ORS) cells and promote hair growth, so it can be used as a health food composition for preventing or improving hair loss.
본 발명에 따른 건강식품 조성물에 있어서, 상기 건강식품은 건강보조식품, 특수 영양 보충용 식품, 기능성 음료 등을 포함할 수 있고, 또는 천연식품, 가공식품 등에 본 발명에 따른 조성물이 첨가될 수 있으나, 이에 제한되는 것은 아니다.In the health food composition according to the present invention, the health food may include health supplements, special nutritional supplement foods, functional drinks, or the like, or the composition according to the present invention may be added to natural foods, processed foods, etc. However, the present invention is not limited thereto.
상기 건강식품 조성물은 유효성분인 상기 티플락스티닌 외에 감미제, 풍미제, 생리활성 성분, 미네랄 등이 더 포함될 수 있다.The health food composition may further include a sweetener, a flavoring agent, a physiologically active ingredient, a mineral, and the like, in addition to the active ingredient, Tiflaxtinin.
상기 건강식품 조성물은 상기 감미제 등 이외에도 필요에 따라 보존제, 유화제, 산미료, 점증제 등을 포함할 수 있다. 이러한 보존제, 유화제 등은 그것이 첨가되는 용도를 달성할 수 있는 한 극미량으로 첨가되어 사용되는 것이 바람직하다. 극미량이란 수치적으로 표현할 때 건강식품 조성물 전체 중량을 기준으로 할 때 0.0005 중량% 내지 약 0.5중량% 범위일 수 있다.The health food composition may include a preservative, an emulsifier, an acidulant, a thickener, and the like, if necessary, in addition to the sweetener. These preservatives, emulsifiers, etc. are preferably added in a trace amount as long as the use to which they are added can be achieved. When expressed numerically, the trace amount may range from 0.0005% by weight to about 0.5% by weight based on the total weight of the health food composition.
또한, 본 발명에 따른 건강식품 조성물은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health food composition according to the present invention may additionally contain food additives, and whether or not it is suitable as a "food additive" is determined by the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the standards and standards for the relevant item.
상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존 료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.Items listed in the "Food Additives Codex", for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as depigmentation, licorice extract, crystalline cellulose, high-cold pigment, and guar gum, L - Mixed preparations, such as sodium glutamate preparation, noodle-added alkali agent, preservative preparation, tar color preparation, etc. are mentioned.
또한, 본 발명은 티플락스티닌(Tiplaxtinin)이 함유된 전달체를 유효성분으로 함유하는 발모 촉진용 조성물을 제공한다.In addition, the present invention provides a composition for promoting hair growth comprising a carrier containing Tiplaxtinin as an active ingredient.
상기 전달체는 치료 부위, 예를 들어 탈모 부위의 두피나 모발로 상기 티플락스티닌을 국소적으로 전달시키거나 또는 분포시켜 치료 효능을 높일 수 있는 제제로, '운반체', '캐리어(carrier)' 등의 용어와 혼용할 수 있으며, 모발에 도포하기에 적당한 혼합물들을 포함할 수 있다.The carrier is an agent capable of increasing the therapeutic efficacy by locally delivering or distributing the tiplaxtinin to the treatment site, for example, the scalp or hair of the hair loss site, 'carrier', 'carrier', etc. It may be used interchangeably with the terms of , and may include mixtures suitable for application to hair.
상기 전달체는 세사미 오일(Sesame oil), 디메틸설폭사이드(Dimethyl sulfoxide), 프로필렌 글리콜(Propylene glycol), 에틸알콜(Ethylalcohol) 및 증류수(H2O)로 이루어진 군에서 선택되는 하나 이상을 포함하여 제조될 수 있다.The carrier may be prepared by including at least one selected from the group consisting of Sesame oil, dimethyl sulfoxide, propylene glycol, ethyl alcohol, and distilled water (H O). .
바람직하게는, 상기 전달체는 세사미 오일, 디메틸설폭사이드 및 프로필렌 글리콜을 포함할 수 있고, 상기 세사미 오일, 디메틸설폭사이드 및 프로필렌 글리콜은 1 : (45 내지 55) : (45 내지 55)의 부피비, 보다 바람직하게는 1 : 49.5 : 49.5의 부피비로 포함될 수 있다.Preferably, the carrier may include sesame oil, dimethyl sulfoxide and propylene glycol, wherein the sesame oil, dimethyl sulfoxide and propylene glycol have a volume ratio of 1: (45 to 55): (45 to 55), more Preferably, it may be included in a volume ratio of 1: 49.5: 49.5.
본 발명의 일 실시예에 따르면, 마우스를 이용한 동물 실험에서, 세사미 오일, 디메틸설폭사이드 및 프로필렌 글리콜로 제조된 운반체에 상기 티플락스티닌을 함유하여 마우스에 처리했을 때, 다른 조성 및 조성비로 제조된 운반체에 비해 현저히 향상된 발모 효과를 확인할 수 있었다.According to an embodiment of the present invention, in an animal experiment using mice, when the tiplaxtinin was contained in a carrier made of sesame oil, dimethyl sulfoxide and propylene glycol, and treated with mice, prepared with different compositions and composition ratios It was confirmed that the hair growth effect was significantly improved compared to the carrier.
본 발명에 따른 발모 촉진용 조성물은 약학 조성물, 화장료 조성물 및 건강식품 조성물로 이루어진 군에서 선택되는 하나 이상일 수 있고, 이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.The composition for promoting hair growth according to the present invention may be one or more selected from the group consisting of a pharmaceutical composition, a cosmetic composition, and a health food composition, and corresponding features may be substituted for the above-mentioned parts.
상기 티플락스티닌은 상기 조성물 전체 100 중량부에 대하여, 0.001 내지 1 중량부, 바람직하게는 0.01 내지 0.5 중량부로 포함될 수 있다. 상기 조성물 함량이 상기 범위 미만이면 탈모 예방 또는 모발 성장 효능·효과가 미약하고, 상기 범위를 초과할 경우에는 제형 안정화에 문제가 있기 때문에 상기 범위가 바람직할 것이다. The tiplaxtinin may be included in an amount of 0.001 to 1 parts by weight, preferably 0.01 to 0.5 parts by weight, based on 100 parts by weight of the total composition. If the composition content is less than the above range, hair loss prevention or hair growth efficacy/effect is weak, and if it exceeds the above range, there is a problem in formulation stabilization, so the above range will be preferable.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to help the understanding of the present invention, examples will be described in detail. However, the following examples are merely illustrative of the contents of the present invention, and the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
<실시예 1> 티플락스티닌 용액(Tiplaxtinin solution) 제조<Example 1> Preparation of Tiplaxtinin solution
티플락스티닌(Tiplaxtinin, Sigma)을 디메틸설폭사이드(dimethyl sulfoxide, DMSO)에 녹인 후, 해당 배지로 희석하여 다양한 농도의 티플락스티닌 용액을 제조하였다. After dissolving Tiplaxtinin (Sigma) in dimethyl sulfoxide (DMSO), it was diluted with the corresponding medium to prepare solutions of Tiplaxtinin at various concentrations.
<실시예 2> 외모근초(Outer Root Sheath, ORS) 세포 배양<Example 2> Outer Root Sheath (ORS) cell culture
외식편(explant)은 일주일 동안 그대로 두다가, 외모근초(ORS) 세포가 배양접시에 부착되어 세포가 뻗어 나오기 시작하면, 3일에 한 번씩 EDGS(EpiLife Defined Growth Supplement) 보충제가 첨가된 EpiLife (gibco)로 바꿔주며, 세포가 자라면 0.25% 트립신(trypsin)/10mM EDTA를 이용하여 세포를 모으고, 5% CO2와 37℃의 조건 하에서 같은 EpiLife (gibco)에서 유지하였다. The explant is left as it is for a week, and when the ORS cells attach to the culture dish and the cells begin to grow, EpiLife (gibco) supplemented with EDGS (EpiLife Defined Growth Supplement) is added once every 3 days. ), and when the cells grow, the cells are collected using 0.25% trypsin/10mM EDTA, and maintained in the same EpiLife (gibco) under the conditions of 5% CO 2 and 37°C.
<실시예 3> 세포 증식 분석<Example 3> Cell proliferation analysis
각 세포의 계대배양 2~3번째 세포에 티플락스티닌 용액을 처리한 후, 세포의 수를 세는 방법(direct counting)을 이용하여 각각의 세포 분화정도를 대조군과 비교하였다. After treating the second and third sub-cultured cells of each cell with the tiplaxtinin solution, the degree of cell differentiation was compared with that of the control group using a direct counting method.
도 1은 본 발명의 일 실시예에 따라 티플락스티닌 용액 처리에 따른 모낭 외모근초세포 수를 나타낸 그래프이다.1 is a graph showing the number of superficial myoblast cells in hair follicles according to the treatment with a tiplaxtinin solution according to an embodiment of the present invention.
도 1을 참조하면, 인간 모낭 외모근초세포에 티플락스티닌 용액을 3일간 처리한 후 세포수를 정량한 결과, 50ng/ml 이하의 농도에서 140~160% 정도의 세포 증식 효과가 나타남을 확인할 수 있다.Referring to FIG. 1 , as a result of quantifying the number of cells after treating human hair follicle superficial myoblast cells with the tiplaxtinin solution for 3 days, it can be seen that a cell proliferation effect of 140 to 160% appears at a concentration of 50 ng/ml or less. there is.
<실시예 4> 모낭조직성장 분석<Example 4> Analysis of hair follicle tissue growth
모발조직 길이측정 실험은 분리되고 다듬어진 모발을 William E medium (gibco)에 24시간 동안 안정화시키고, 약물(티플락스티닌)을 농도별 처리한 후 자라나온 모 조직 길이를 측정하고 2일에 한 번씩 새로운 배지로 바꿔주었다. In the hair tissue length measurement experiment, separated and trimmed hair was stabilized in William E medium (gibco) for 24 hours, and the length of the grown hair tissue was measured after treatment with the drug (tiflaxtinin) by concentration, and once every 2 days. exchanged for a new badge.
티플락스티닌 용액의 5가지 농도 (0, 62.5, 125, 250, 500ng/ml)를 모발조직 길이측정 실험에 사용하였다. 각 농도 당 6~11개의 모발을 다섯 명의 각기 다른 실제 환자 후두부 모발을 분리한 후, 약물을 처리하여 1, 3, 5, 7, 9일에 자라나온 모발의 길이를 측정하였고, 대조군 대비 모발성장촉진%를 계산하여 그 효과를 평가하였다. Five concentrations (0, 62.5, 125, 250, 500 ng/ml) of the tiplaxtinin solution were used in the hair tissue length measurement experiment. After separating the occipital hairs from 5 different actual patients from 6 to 11 hairs at each concentration, the length of hair grown on
도 2는 본 발명의 일 실시예에 따른 티플락스티닌 용액 처리 농도별 상대적 모발 길이 변화를 측정한 결과이다.2 is a result of measuring the relative hair length change according to the treatment concentration of the tiplaxtinin solution according to an embodiment of the present invention.
도 2를 참조하면, 환자 후두부의 모발을 분리하여 조직배양환경을 만들어 준 후 각각 0, 62.5, 125, 250, 500 ng/ml의 농도로 처리한 결과, 5명의 각기 다른 환자 모두와 실험되어진 전 농도에서 대조군 대비 130~150%의 발모 촉진 효과를 보였다. 5명의 환자 평균 모발성장촉진은 9일 동안 약물을 처리한 후 이들의 최종 상태의 모발 길이를 잰 것으로 모발 자체가 대조군에 비해 더 길게 자라나오는 것을 볼 수 있었다.Referring to FIG. 2 , after separating the hairs of the patient's occipital region to create a tissue culture environment, treatment with concentrations of 0, 62.5, 125, 250, and 500 ng/ml, respectively, was performed with all 5 different patients. It showed a hair growth promoting effect of 130-150% compared to the control at the concentration. The average hair growth promotion of 5 patients was measured by measuring their final hair length after treatment with the drug for 9 days, and it could be seen that the hair itself grew longer than the control group.
<실시예 5> 동물 실험<Example 5> Animal experiment
휴지기(Telogen) 마우스 7주령(female) 각 7마리의 등을 면도한 후 운반체(vehicle) 군(대조군)과 운반체에 티플락스티닌(100μg/ml)을 섞어 바르는 군으로 분류하여 4주간 주 5일 도포한 후 관찰하였다. 운반체의 조성은 세사미 오일(Sesame oil), DMSO, 프로필렌 글리콜(Propylene glycol)을 각각 1 : 49.5 : 49.5 (vol/vol)의 비율로 혼합하여 사용하였다.Telogen mice 7 weeks old (female) After shaving the backs of each 7 mice, they were classified into a vehicle group (control group) and a group where tiplaxtinin (100 μg/ml) was mixed with the vehicle and applied for 4
도 3은 본 발명의 일 실시예에 따른 동물 실험의 결과를 나타낸 이미지이다.3 is an image showing the results of an animal experiment according to an embodiment of the present invention.
도 3을 참조하면, 휴지기 시기의 면도된 7주령(female) 마우스의 등에 대조군(운반체 군)과 약물(100μg/ml Tiplaxtinin)이 섞인 운반체 군을 약 4주간 바른 결과, 대조군 보다 월등한 발모 효과를 일관성 있게 관찰할 수 있었다. Referring to Figure 3, the control group (carrier group) and the carrier group mixed with the drug (100 μg/ml Tiplaxtinin) were applied to the back of a shaved 7-week-old (female) mouse in the resting period for about 4 weeks. As a result, a superior hair growth effect was obtained than the control group. could be observed consistently.
<실시예 6> 티플락스티닌 운반체(vehicle) 조성비에 따른 발모 효과 비교<Example 6> Comparison of hair growth effect according to the composition ratio of tiplaxtinin vehicle (vehicle)
증류수(H2O), 에틸알콜(ethylalcohol, EtOH), 프로필렌 글리콜(Propylene glycol, PG), 디메틸설폭사이드(dimethyl sulfoxide, DMSO), 세사미 오일(Sesame oil, SO)의 조성비에 따른 티플락스티닌 운반체를 제조하여 이의 발모 효과를 비교하였다. Tiflaxtinin carrier according to the composition ratio of distilled water (H 2 O), ethyl alcohol (ethylalcohol, EtOH), propylene glycol (PG), dimethyl sulfoxide (DMSO), and sesame oil (SO) was prepared and its hair growth effect was compared.
적정 농도의 티플락스티닌이 녹아 있는 DMSO 용액에 증류수, 에틸알콜, 프로필렌 글리콜 또는 세사미 오일을 일정 비율로 섞어 제조한 용액을 첨가하여 1분간의 소니케이션(sonication)과 5분간 볼텍스(vortex)를 번갈아 진행하면서 잘 섞어주었다.Add a solution prepared by mixing distilled water, ethyl alcohol, propylene glycol, or sesame oil in a certain ratio to a DMSO solution in which Tiflaxtinin is dissolved at an appropriate concentration, and alternate sonication for 1 minute and vortex for 5 minutes. Mix well as you proceed.
표 1은 본 발명의 일 실시예에 따른 티플락스티닌 운반체 조성비 및 상기 조성비에 따른 발모 효과를 비교한 것이다.Table 1 compares the composition ratio of the tiplaxtinin carrier according to an embodiment of the present invention and the hair growth effect according to the composition ratio.
표 1을 참조하면, 증류수 없이 세사미 오일(SO), 디메틸설폭사이드(DMSO) 및 프로필렌 글리콜(PG)이 1 : 49.5 : 49.5의 비율로 조성된 운반체를 사용하였을 때, 발모성장 비율이 가장 높은 것으로 나타났다.Referring to Table 1, when using a carrier composed of sesame oil (SO), dimethyl sulfoxide (DMSO) and propylene glycol (PG) in a ratio of 1: 49.5: 49.5 without distilled water, the hair growth ratio is the highest. appear.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.As described above in detail a specific part of the content of the present invention, for those of ordinary skill in the art, it is clear that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereby. do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (9)
상기 티플락스티닌은,
모낭 외모근초(ORS) 세포를 증식시키고, 모발 성장을 촉진시키는 것을 특징으로 하는 탈모 예방 또는 치료용 약학 조성물.The method of claim 1,
The tiplaxtinin is
A pharmaceutical composition for preventing or treating hair loss, characterized in that it proliferates hair follicle outer root sheath (ORS) cells and promotes hair growth.
상기 조성물은,
헤어토닉, 헤어크림, 헤어에센스, 헤어로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어스프레이, 헤어에어졸, 헤어팩, 헤어왁스, 헤어염색제 또는 헤어젤의 제형을 갖는 것을 특징으로 하는 탈모 예방 또는 개선용 화장료 조성물.4. The method of claim 3,
The composition is
Hair tonic, hair cream, hair essence, hair lotion, hair shampoo, hair rinse, hair treatment, hair spray, hair aerosol, hair pack, hair wax, hair dye or hair gel, characterized in that having the formulation of hair loss prevention or improvement cosmetic composition for use.
상기 전달체는,
세사미 오일(Sesame oil), 디메틸설폭사이드(Dimethyl sulfoxide), 프로필렌 글리콜(Propylene glycol), 에틸알콜(Ethylalcohol) 및 증류수(H2O)로 이루어진 군에서 선택되는 하나 이상을 포함하는 것을 특징으로 하는 발모 촉진용 조성물.7. The method of claim 6,
The carrier is
Hair growth comprising at least one selected from the group consisting of Sesame oil, dimethyl sulfoxide, propylene glycol, ethyl alcohol, and distilled water (H 2 O) A composition for promotion.
상기 전달체는 세사미 오일, 디메틸설폭사이드 및 프로필렌 글리콜을 포함하고,
상기 세사미 오일, 디메틸설폭사이드 및 프로필렌 글리콜은 1 : (45 내지 55) : (45 내지 55)의 부피비로 포함되는 것을 특징으로 하는 발모 촉진용 조성물.7. The method of claim 6,
The carrier comprises sesame oil, dimethyl sulfoxide and propylene glycol,
The sesame oil, dimethyl sulfoxide and propylene glycol are 1: (45 to 55): A composition for promoting hair growth, characterized in that it is included in a volume ratio of (45 to 55).
상기 조성물은,
약학 조성물, 화장료 조성물 및 건강식품 조성물로 이루어진 군에서 선택되는 하나 이상인 것을 특징으로 하는 발모 촉진용 조성물.7. The method of claim 6,
The composition is
A composition for promoting hair growth, characterized in that at least one selected from the group consisting of a pharmaceutical composition, a cosmetic composition, and a health food composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200005397A KR102386651B1 (en) | 2020-01-15 | 2020-01-15 | Composition for preventing or treating hair loss comprising tiplaxtinin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200005397A KR102386651B1 (en) | 2020-01-15 | 2020-01-15 | Composition for preventing or treating hair loss comprising tiplaxtinin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210091992A true KR20210091992A (en) | 2021-07-23 |
| KR102386651B1 KR102386651B1 (en) | 2022-04-14 |
Family
ID=77155353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200005397A KR102386651B1 (en) | 2020-01-15 | 2020-01-15 | Composition for preventing or treating hair loss comprising tiplaxtinin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102386651B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060058369A1 (en) * | 2002-02-19 | 2006-03-16 | Vanderbilt University | Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors |
| US20070189980A1 (en) * | 2004-06-07 | 2007-08-16 | Jie Zhang | Compositions and methods for treating alopecia |
| KR20110064989A (en) | 2009-12-09 | 2011-06-15 | 경북대학교 산학협력단 | A composition for preventing or treating baldness comprising alpha-lipoic acid |
-
2020
- 2020-01-15 KR KR1020200005397A patent/KR102386651B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060058369A1 (en) * | 2002-02-19 | 2006-03-16 | Vanderbilt University | Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors |
| US20070189980A1 (en) * | 2004-06-07 | 2007-08-16 | Jie Zhang | Compositions and methods for treating alopecia |
| KR20110064989A (en) | 2009-12-09 | 2011-06-15 | 경북대학교 산학협력단 | A composition for preventing or treating baldness comprising alpha-lipoic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102386651B1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5635226B2 (en) | Hair papilla cell growth promoter | |
| JP4603192B2 (en) | Hair scalp composition | |
| EP0998907B1 (en) | Hair tonic composition comprising adenosine | |
| JP5166116B2 (en) | Hair restorer | |
| JP5216414B2 (en) | Hair restorer | |
| KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
| KR20160029769A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| KR20120051199A (en) | Cosmetic compositions for hair or scalp to prevent hair loss and promote growing hair | |
| JP4032246B2 (en) | White hair prevention and improvement agent | |
| US20070116658A1 (en) | Hair tonic composition | |
| CN112220794B (en) | Application of limonin in preventing alopecia and promoting hair growth | |
| JP2009091325A (en) | Hair growth agent | |
| JP7135106B2 (en) | Scalp and hair composition | |
| KR101578849B1 (en) | Shampoo or conditioner composition containing Ginsenoside C-Mx1 for promoting hair growth by strengthen the scalp and the hair roots | |
| KR100476069B1 (en) | A composition for trichogenousness or preventing the depilation containing 1,2-dithiolthione derivative | |
| JP3542700B2 (en) | Head composition | |
| CN113058026B (en) | Application of Kisspeptin-234 in promoting hair growth | |
| JPH11302131A (en) | Cosmetic for scalp and hair | |
| CN112494488B (en) | Application of rebamipide in preventing alopecia and growing hair | |
| KR20150051075A (en) | A body hair growth inhibition composition comprising palmatine as an effective ingredient | |
| KR101984276B1 (en) | A body hair growth inhibition composition comprising berberine hydrochloride as an effective ingredient | |
| EP2857002A1 (en) | Composition for hair growth | |
| KR20150085964A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Wogonin | |
| KR20240001370A (en) | Composition for promoting hair growth | |
| CN112057459A (en) | Application of kahweol in preventing alopecia and promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |